Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2024-11-05 Delisting Announcement
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
Delisting Announcement Classification · 100% confidence The document is an 'Ad hoc announcement' dated November 5, 2024, explicitly stating that 'Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.' The core subject is the impending removal of the company's stock from the exchange, referencing the SIX Listing Rules (LR) regarding suspension and cancellation of listing. This directly corresponds to the definition of a Delisting Announcement (DLST). The document length (4969 chars) is short, but the content is the announcement itself, not a notification about an attached report, making DLST the most accurate classification.
2024-11-05 English
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
Delisting Announcement Classification · 100% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' from Spexis AG. The core subject matter explicitly states: 'Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.' This directly relates to the removal of the company's stock from the exchange. Based on the provided definitions, the category 'Delisting Announcement' (DLST) is the most appropriate classification.
2024-11-05 English
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Legal Proceedings Report Classification · 99% confidence The document is labeled as an 'Ad-hoc' announcement released on July 29, 2024, pursuant to 'Art. 53 LR' (Listing Rules). It discusses a specific legal/corporate event: the granting of 'definitive moratorium status' by a court. This type of immediate, material, non-periodic corporate event disclosure, especially concerning legal status or restructuring, typically falls under general regulatory announcements or specific legal/corporate action categories. Since it is not a standard financial report (10-K, IR, ER), nor a management change (MANG), nor a director dealing (DIRS), nor a dividend notice (DIV), the most appropriate general category for an immediate, material, non-standard regulatory disclosure is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered by more specific codes. The document length is short (4496 chars), but it is the primary announcement itself, not just a notice *about* an attached report, so RPA is less suitable than RNS for this specific legal update.
2024-07-29 English
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Legal Proceedings Report Classification · 99% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' from Spexis AG, dated July 29, 2024. It details a legal/regulatory event: the granting of a definitive moratorium status by a court, subject to progress reporting. This type of announcement, which communicates significant, non-routine corporate events (like legal proceedings, restructuring status, or major operational updates) that are not standard periodic financial reports (10-K, IR, ER), typically falls under general regulatory disclosure mechanisms. Since the content specifically relates to legal proceedings (court status, moratorium) and is an immediate, unscheduled disclosure ('Ad hoc'), it best fits the 'Legal Proceedings Report' (LTR) category if the focus is the legal status, or the general 'Regulatory Filings' (RNS) category as a catch-all for ad hoc disclosures not covered elsewhere. Given the core subject is the court-mandated moratorium and reporting obligations, LTR is a strong candidate, but RNS is often used for general ad hoc market-sensitive news that isn't strictly a financial report or a director dealing. Since the document is a direct, immediate announcement of a significant legal/restructuring status update, and LTR covers 'significant lawsuits, regulatory actions, or legal matters,' I will classify it as LTR. However, because it is an 'Ad hoc announcement' which is a common format for general market disclosures in European markets, RNS is also plausible. Given the specific mention of court action and moratorium, LTR is more precise than the general RNS fallback.
2024-07-29 English
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Companys moratorium and changes to its Executive Committee.
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc announcement pursuant to Art. 53 LR" and is dated July 22, 2024. The content discusses several critical, non-periodic corporate events: the expected delay in completing the 2023 financial audit, an update on the company's moratorium status, and changes in senior management (Executive Committee). While it mentions the 2023 financials, the primary purpose is to disseminate timely, material, non-scheduled information regarding legal/financial status and management changes, rather than being the full financial report (10-K or IR) or a standard earnings release (ER). The key topics covered are management changes (MANG) and significant legal/financial status updates (LTR/CAP). Since it is an unscheduled, material announcement released outside of regular reporting cycles, and it contains specific management changes, it fits best under the general regulatory announcement category, which is RNS, or potentially MANG if the management change was the sole focus. However, given the mix of audit delay, moratorium status, and management changes, it functions as a broad regulatory disclosure. Since there is no specific category for 'Ad-hoc Status Update,' RNS (Regulatory Filings) is the most appropriate fallback for this type of immediate, material disclosure that isn't a standard periodic report or a specific event like a dividend or M&A.
2024-07-22 English
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
Legal Proceedings Report Classification · 99% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and is released on July 22, 2024. It discusses several immediate, non-periodic corporate events: the expected delay in completing the 2023 financial audit, the status of a provisional debt moratorium, and changes in the Executive Committee (management changes). This type of immediate, material information release, often mandated by stock exchange rules (like Art. 53 LR, common in Switzerland), is best classified as a general Regulatory Filing (RNS) or potentially related to Management Information (MANG) due to the executive changes. However, since it covers multiple critical, time-sensitive updates (audit delay, moratorium status, management changes) that don't fit neatly into specific financial report categories (like 10-K or ER), and it is explicitly labeled as an 'Ad hoc announcement' under regulatory rules, the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered elsewhere. It is not a full report (10-K, IR), a presentation (IP), or a specific management compensation report (DEF 14A).
2024-07-22 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.